```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, represents a valuable laboratory reagent extensively employed in thrombosis studies . This antibody fragment specifically targets the glycoprotein IIb/IIIa complex on thrombocytes , preventing thrombus development. As a result, it's frequently investigated as a technique to explore the mechanisms underlying thrombosis and to evaluate the efficacy of anticoagulant therapies. Availability is typically limited to institutional settings.
```
Abciximab Drug Research: Utilizing The C7E3 Fragment and Compound 143653-53-6 in Scientific Assessments
Ongoing research into abciximab, a GPIIb/IIIa, frequently employs the monoclonal antigen C7E3 and the substance identified as 143653-53-6. These materials are essential for analyzing abciximab's biological activity, determining its therapeutic effect in different patient populations, and understanding potential indicators of patient outcome. Continued investigation leveraging these specific reagents is predicted to generate valuable data for improving patient care related to cardiovascular conditions.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce Abciximab antibody intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Investigating Research Opportunities with the Drug Abciximab 143653-53-6 and C7E3
Recent research suggest that the drug (identified as 143653-53-6) holds significant research potential, particularly when paired with C7E3. Preliminary findings have that this association could boost patient responses in multiple heart-related settings. Further exploration is directed on defining the exact process of effect between the antiplatelet medication and C7E3, encompassing assessment of blood clot cohesion and arterial safeguarding.
- Ongoing investigation endeavors seek to optimize administration strategies.
- Laboratory models are being employed to further validate such theories.
- Human trials might be required to thoroughly determine patient benefit.
```
Abciximab (C7E3) for Research: Specifications and Specifications (143653-53-6)
Researchers seeking abciximab for experimental studies should meticulously assess purity and defined characteristics. Material 143653-53-6 is typically offered as a lyophilized powder and detailed analytical information including identity by LC-MS, potency assays, and bacterial endotoxin testing must be available. Verify the manufacturer's certificate of analysis clearly states required limits for impurities and conforms to all QC standards .
High-Purity C7E3 Details & Stock
Acquiring laboratory-grade Abciximab, specifically referencing the molecule C7E3 and identified by the product number 143653-53-6, requires thorough consideration of its origin . This glycoprotein is frequently utilized in cell-based studies , particularly those related to platelet clumping and occlusion. Current suppliers offer this material in varying amounts , typically ranging from g to substantial wholesale amounts . Kindly recommend reviewing the documentation of quality to verify quality and suitability for your specific application . Furthermore , check the expiration date before purchasing to maintain optimal performance .
- Standard Purity: >95%
- Storage Conditions: -20°C in controlled conditions
- Use : Platelet Adhesion Inhibition Studies